Post-Exposure Prophylaxis

Following the June update that allowed for a lower dose of Regeneron’s antibody cocktail to treat COVID-19, the FDA has again expanded emergency use authorization, this time allowing for its use as post-exposure prophylaxis.

The FDA has expanded the approval of baloxavir marboxil to include postexposure prophylaxis for influenza in patients aged 12 years or older who have had contact with an infected person.

A study conducted at dozens of primary care clinics in Japan showed that household contacts of people with influenza were 86% less likely to develop influenza after receiving a single dose of baloxavir marboxil as postexposure prophylaxis.

Judith Feinberg, MD, from West Virginia University School of Medicine, spoke with Healio about important FDA approvals in HIV, the burden of drug resistance, threats to HIV control and the future of HIV treatment.